Leading technology companies like Alibaba, Microsoft and NVIDIA have made available their key technologies to help researchers and scientists find a solution to mitigate the Covid-19 outbreak.
Microsoft
Microsoft has partnered with Adaptive Biotechnologies to leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease, augmenting existing research efforts that primarily focus on the biology of the virus. These data will be made freely available to any researcher, public health official or organization around the world via an open data access portal.
NVIDIA
NVIDIA announced that it is sharing tools with researchers that can accelerate their race to understand the novel coronavirus and help inform a response.
NVIDIA said it will provide a free 90-day license to Parabricks to any researcher in the worldwide effort to fight the novel coronavirus. Based on the well-known Genome Analysis Toolkit, Parabricks uses GPUs to accelerate by as much as 50x the analysis of sequence data. Researchers are sequencing both the novel coronavirus and the genomes of people afflicted with COVID-19 to understand, among other things, the spread of the disease and who is most affected. But analyzing genomic sequences takes time and computing muscle.
Alibaba Cloud
Alibaba Cloud announced that it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.
The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.
The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud's solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.
